Nasdaq · Healthcare
Zenas BioPharma, Inc. (ZBIO)
As-reported financials and recent SEC filings for Zenas BioPharma, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$10.0M
Net income
$-377.7M
Net margin
—
Diluted EPS
$-8.44
ROE
-156.0%
P/E (TTM)
—
Market cap
—
Debt / equity
0.3×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2024 |
|---|---|---|---|
| Revenue | $10.0M | $5.0M | $50.0M |
| Gross profit | — | — | — |
| Operating income | $-383.1M | $-163.9M | $-37.1M |
| Net income | $-377.7M | $-157.0M | $-37.1M |
| Diluted EPS | $-8.44 | $-3.96 | $-0.90 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →Largest Healthcare peers
Go deeper on ZBIO
Search Zenas BioPharma, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.